4th Quarter - Report

W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

P.L. 114-113: "Consolidated Appropriations Act" with respect to the Protecting Americans from Tax Hikes Act and provisions related to delay in the medical device tax.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Promoted life sciences community and communicated economic and health benefits of the industry. H.R. 6: 21st Century Cures Act and Senate HELP Committee companion effort to promote medical innovation for patients, specifically with respect to reforms at NIH. Education about the value of innovative new medicines. Education about FDA performance on review of drugs and medical devices. H.R. 3513/S. 2023: Prescription Drug Affordability Act of 2015. Education about the importance of adequate funding for NIH.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2023 (114th), H.R. 3513 (114th), H.R. 6 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.